This inventor holds 22 USPTO granted patents and 13 published patent applications. Top assignees: Procom One, Inc., Pernix Sleep, Inc., Currax Pharmaceuticals LLC. Active years: 1996-2024.
Location History:
- Chappagua, NY (US) (1996)
- Chappaqua, NY (US) (1997 - 2024)
Company Filing History:
15 out of 16 
9 out of 13 
8 out of 13 Years Active: 1996-2024
Title: Neil Barton Kavey: Innovator in Sleep Medicine
Introduction
Neil Barton Kavey, based in Chappaqua, NY, has made significant contributions to the field of sleep medicine with an impressive portfolio of 22 patents. His innovative approaches focus on treating sleep disorders, particularly using low-dose doxepin, which has garnered attention and respect in the medical community.
Latest Patents
Among his recent patents, Kavey has developed methods aimed at improving sleep quality and efficiency. One notable patent details "Methods of using low-dose doxepin for the improvement of sleep," specifically targeting the prevention of early awakenings and enhancing sleep efficiency in the later hours of a sleep cycle. This involves the administration of low doses of doxepin, typically ranging from 1 to 6 mg.
Another significant contribution is his patent titled "Low-dose doxepin for treatment of sleep disorders in elderly patients." This work highlights methods for treating insomnia in elderly individuals aged 65 years and older by administering initial daily dosages of doxepin at 1 to 3 mg. His research indicates that these ultra-low dosages are particularly effective for elderly patients, improving wake time during sleep and reducing latency to persistent sleep, making a substantial impact on sleep quality for this demographic.
Career Highlights
Kavey's career includes influential positions in companies such as Procom One, Inc. and Pernix Sleep, Inc. His work has consistently focused on enhancing understanding and treatment options for sleep disorders, leading to advancements in therapeutic approaches that benefit various patient populations.
Collaborations
Collaboration has played a pivotal role in Kavey's success. He has had the privilege of working alongside esteemed colleagues such as Susan E. Dubé and Philip Jochelson. Their combined expertise has contributed to the development of innovative treatment methodologies that advance the field of sleep medicine.
Conclusion
Neil Barton Kavey stands out as a dedicated innovator in sleep medicine, with a robust portfolio of patents that demonstrate his commitment to improving patient outcomes. His work not only highlights the potential for low-dose doxepin in treating sleep disorders but also emphasizes the importance of tailored approaches for specific populations, particularly the elderly. As research continues to evolve, Kavey's contributions will undoubtedly play a crucial role in shaping future sleep therapies.